Abstract
Pharmacokinetics of radiolabeled BrE-3 monoclonal antibody (Mab), reactive against a breast mucin epitope, were assessed in 15 patients with advanced breast cancer. Patients received 5 mCi (185 MBq) of 111In-methyl benzyl isothiocyanate DTPA (MX-DTPA) conjugated BrE-3 Mab intravenously with total antibody doses of 10, 50 or 100 mg. Serial quantitative imaging, blood and urine clearance were obtained to measure pharmacokinetics, assess tumor localization and estimate radiation dose. Organ function was followed to determine toxicity. Mild allergic reactions occurred in four patients. Eighty-six percent of 70 known lesions and 5 unsuspected lesions were detected by antibody imaging. Biexponential modeling of radiolabeled antibody in serum showed a T( 1/2 (α)) = 9.5 ± 2.7 hr and T( 1/2 (β)) = 56 ± 25.4 hr. Total urinary excretion averaged 35.5% ± 19.3% injected dose (ID) by Day 8. Quantitative imaging showed that 0.02-2.56%ID localized in tumors. Extrapolating dosimetry from 111In-MX-DTPA-BrE-3 to 90Y-MX-DTPA-BrE-3, we estimate therapeutic radiation doses could be delivered to some tumors with tolerable toxicity.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1067-1074 |
| Number of pages | 8 |
| Journal | Journal of Nuclear Medicine |
| Volume | 34 |
| Issue number | 7 |
| State | Published - 1993 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Radiological and Ultrasound Technology
Cite this
Radioimmunolocalization of metastatic breast carcinoma using indium-111- methyl benzyl DTPA BrE-3 monoclonal antibody : Phase I study. / Kramer, E. L.; DeNardo, S. J.; Liebes, L.; Kroger, L. A.; Noz, M. E.; Mizrachi, H.; Salako, Q. A.; Furmanski, P.; Glenn, S. D.; Denardo, Gerald L; Ceriani, R.
In: Journal of Nuclear Medicine, Vol. 34, No. 7, 1993, p. 1067-1074.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Radioimmunolocalization of metastatic breast carcinoma using indium-111- methyl benzyl DTPA BrE-3 monoclonal antibody
T2 - Phase I study
AU - Kramer, E. L.
AU - DeNardo, S. J.
AU - Liebes, L.
AU - Kroger, L. A.
AU - Noz, M. E.
AU - Mizrachi, H.
AU - Salako, Q. A.
AU - Furmanski, P.
AU - Glenn, S. D.
AU - Denardo, Gerald L
AU - Ceriani, R.
PY - 1993
Y1 - 1993
N2 - Pharmacokinetics of radiolabeled BrE-3 monoclonal antibody (Mab), reactive against a breast mucin epitope, were assessed in 15 patients with advanced breast cancer. Patients received 5 mCi (185 MBq) of 111In-methyl benzyl isothiocyanate DTPA (MX-DTPA) conjugated BrE-3 Mab intravenously with total antibody doses of 10, 50 or 100 mg. Serial quantitative imaging, blood and urine clearance were obtained to measure pharmacokinetics, assess tumor localization and estimate radiation dose. Organ function was followed to determine toxicity. Mild allergic reactions occurred in four patients. Eighty-six percent of 70 known lesions and 5 unsuspected lesions were detected by antibody imaging. Biexponential modeling of radiolabeled antibody in serum showed a T( 1/2 (α)) = 9.5 ± 2.7 hr and T( 1/2 (β)) = 56 ± 25.4 hr. Total urinary excretion averaged 35.5% ± 19.3% injected dose (ID) by Day 8. Quantitative imaging showed that 0.02-2.56%ID localized in tumors. Extrapolating dosimetry from 111In-MX-DTPA-BrE-3 to 90Y-MX-DTPA-BrE-3, we estimate therapeutic radiation doses could be delivered to some tumors with tolerable toxicity.
AB - Pharmacokinetics of radiolabeled BrE-3 monoclonal antibody (Mab), reactive against a breast mucin epitope, were assessed in 15 patients with advanced breast cancer. Patients received 5 mCi (185 MBq) of 111In-methyl benzyl isothiocyanate DTPA (MX-DTPA) conjugated BrE-3 Mab intravenously with total antibody doses of 10, 50 or 100 mg. Serial quantitative imaging, blood and urine clearance were obtained to measure pharmacokinetics, assess tumor localization and estimate radiation dose. Organ function was followed to determine toxicity. Mild allergic reactions occurred in four patients. Eighty-six percent of 70 known lesions and 5 unsuspected lesions were detected by antibody imaging. Biexponential modeling of radiolabeled antibody in serum showed a T( 1/2 (α)) = 9.5 ± 2.7 hr and T( 1/2 (β)) = 56 ± 25.4 hr. Total urinary excretion averaged 35.5% ± 19.3% injected dose (ID) by Day 8. Quantitative imaging showed that 0.02-2.56%ID localized in tumors. Extrapolating dosimetry from 111In-MX-DTPA-BrE-3 to 90Y-MX-DTPA-BrE-3, we estimate therapeutic radiation doses could be delivered to some tumors with tolerable toxicity.
UR - http://www.scopus.com/inward/record.url?scp=0027176884&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027176884&partnerID=8YFLogxK
M3 - Article
C2 - 8315480
AN - SCOPUS:0027176884
VL - 34
SP - 1067
EP - 1074
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
SN - 0161-5505
IS - 7
ER -